Pay vs Performance Disclosure - USD ($)
May 31, 2025
May 31, 2024
May 31, 2023
May 31, 2022
May 31, 2021
| Fiscal Year | Summary Compensation Table Total for the CEO (1) | Compensation Actually Paid to the CEO (3)(4) | Average Summary Compensation Table Total for Non-CEO NEOs (2) | Average Compensation Actually Paid to the Non-CEO NEOs (3)(4) | Total Shareholder Return (5) | Peer Group Total Shareholder Return (5) | Net Income (loss) (in thousands) (6) | Revenue (in thousands) (7) | ||||||||||||||||||
| 2025 | $ | 5,494,284 | $ | 6,807,600 | $ | 1,466,609 | $ | 4,144,464 | $ | 44.12 | $ | 42.92 | $ | (33,993) | $ | 292,498 | ||||||||||
| 2024 | $ | 5,005,971 | $ | 971,112 | $ | 1,264,817 | $ | 656,573 | $ | 61.80 | $ | 52.56 | $ | (184,350) | $ | 303,914 | ||||||||||
| 2023 | $ | 3,983,690 | $ | (2,114,483) | $ | 914,244 | $ | (45,199) | $ | 92.65 | $ | 69.71 | $ | (52,441) | $ | 338,752 | ||||||||||
| 2022 | $ | 5,659,727 | $ | 4,953,581 | $ | 1,303,492 | $ | 1,233,726 | $ | 192.26 | $ | 73.12 | $ | (26,547) | $ | 316,219 | ||||||||||
| 2021 | $ | 4,045,913 | $ | 13,883,392 | $ | 1,029,527 | $ | 2,868,533 | $ | 226.44 | $ | 124.10 | $ | (31,547) | $ | 291,010 | ||||||||||
| 2025 | 2024 | 2023 | 2022 | ||||||||||||||||||||||||||||||||||||||||||||
| CEO | Average of Non-CEO NEOs | CEO | Average of Non-CEO NEOs | CEO | Average of Non-CEO NEOs | CEO | Average of Non-CEO NEOs | ||||||||||||||||||||||||||||||||||||||||
| Total Compensation from SCT | $ | 5,494,284 | $ | 1,466,609 | $ | 5,005,971 | $ | 1,264,817 | $ | 3,983,690 | $ | 914,244 | $ | 5,659,727 | $ | 1,303,492 | |||||||||||||||||||||||||||||||
| Subtractions: | |||||||||||||||||||||||||||||||||||||||||||||||
| SCT Value of Stock and Option Awards | $ | (3,437,078) | $ | (734,299) | $ | (3,399,217) | $ | (592,487) | $ | (3,000,774) | $ | (454,289) | $ | (4,147,712) | $ | (687,958) | |||||||||||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||
| Unvested value at year end of equity granted during the covered fiscal year | $ | 3,736,553 | $ | 3,217,933 | $ | 817,462 | $ | 226,197 | $ | 658,535 | $ | 99,697 | $ | 3,289,559 | $ | 518,057 | |||||||||||||||||||||||||||||||
| Change from prior year end in fair value of awards granted in any prior fiscal year that are outstanding and unvested at covered year end | $ | 1,263,456 | $ | 243,529 | $ | (313,264) | $ | (42,700) | $ | (3,867,465) | $ | (612,420) | $ | (1,051,502) | $ | (189,282) | |||||||||||||||||||||||||||||||
| Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal years for which vesting conditions were satisfied at the end of or during the covered fiscal year | $ | (249,615) | $ | (49,308) | $ | (1,139,840) | $ | (199,254) | $ | 111,531 | $ | 7,569 | $ | 1,203,509 | $ | 289,417 | |||||||||||||||||||||||||||||||
| Compensation Actually Paid | $ | 6,807,600 | $ | 4,144,464 | $ | 971,112 | $ | 656,573 | $ | (2,114,483) | $ | (45,199) | $ | 4,953,581 | $ | 1,233,726 | |||||||||||||||||||||||||||||||
| 2025 | 2024 | 2023 | 2022 | ||||||||||||||||||||||||||||||||||||||||||||
| CEO | Average of Non-CEO NEOs | CEO | Average of Non-CEO NEOs | CEO | Average of Non-CEO NEOs | CEO | Average of Non-CEO NEOs | ||||||||||||||||||||||||||||||||||||||||
| Total Compensation from SCT | $ | 5,494,284 | $ | 1,466,609 | $ | 5,005,971 | $ | 1,264,817 | $ | 3,983,690 | $ | 914,244 | $ | 5,659,727 | $ | 1,303,492 | |||||||||||||||||||||||||||||||
| Subtractions: | |||||||||||||||||||||||||||||||||||||||||||||||
| SCT Value of Stock and Option Awards | $ | (3,437,078) | $ | (734,299) | $ | (3,399,217) | $ | (592,487) | $ | (3,000,774) | $ | (454,289) | $ | (4,147,712) | $ | (687,958) | |||||||||||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||
| Unvested value at year end of equity granted during the covered fiscal year | $ | 3,736,553 | $ | 3,217,933 | $ | 817,462 | $ | 226,197 | $ | 658,535 | $ | 99,697 | $ | 3,289,559 | $ | 518,057 | |||||||||||||||||||||||||||||||
| Change from prior year end in fair value of awards granted in any prior fiscal year that are outstanding and unvested at covered year end | $ | 1,263,456 | $ | 243,529 | $ | (313,264) | $ | (42,700) | $ | (3,867,465) | $ | (612,420) | $ | (1,051,502) | $ | (189,282) | |||||||||||||||||||||||||||||||
| Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal years for which vesting conditions were satisfied at the end of or during the covered fiscal year | $ | (249,615) | $ | (49,308) | $ | (1,139,840) | $ | (199,254) | $ | 111,531 | $ | 7,569 | $ | 1,203,509 | $ | 289,417 | |||||||||||||||||||||||||||||||
| Compensation Actually Paid | $ | 6,807,600 | $ | 4,144,464 | $ | 971,112 | $ | 656,573 | $ | (2,114,483) | $ | (45,199) | $ | 4,953,581 | $ | 1,233,726 | |||||||||||||||||||||||||||||||
| (1) | TSR represents the value of a $100 investment in common stock, assuming reinvestment of dividends, as measured at each fiscal year end. | ||||
| (1) | TSR represents the value of a $100 investment in common stock, assuming reinvestment of dividends, as measured at each fiscal year end. | ||||
•EBITDA and EPS; and
•The Company Selected Measure is Revenue.
•Restricted stock units: The fair value of restricted stock units was based on the Company's closing stock price on each measurement date.
•Non-qualified stock options: The fair value of non-qualified stock options was determined using a Black-Scholes option pricing model.
•Performance unit awards: Performance unit awards are subject to vesting based on the Company's level of attainment of performance targets, as well as a TSR modifier at the end of each performance period that can adjust the aggregate number of shares eligible to vest at the end of the three-year performance period. The fair value for performance unit awards was determined using a Monte Carlo simulation.
Total shareholder return (TSR) is determined based on the value of an initial fixed investment of $100 in common stock on May 31, 2020, assuming the reinvestment of the dividends. The TSR peer group comprises the RDG SmallCap Medical Devices Index.Reflects the dollar amount of net income reported in our audited financial statements for the applicable fiscal year. GAAP Revenue equals Net Revenue, so no reconciliations are required for fiscal years 2025, 2024, 2023, 2022 or 2021. See our 2025 Annual Report on Form 10-K for the year ended May 31, 2025.